FT-011 is under clinical development by Certa Therapeutics and currently in Phase II for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase II drugs for Systemic Sclerosis (Scleroderma) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how FT-011’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
FT-011 overview
FT-011 (SHP-627) is under development for the treatment of systemic sclerosis, idiopathic pulmonary fibrosis, chronic kidney disease and glaucoma. The drug candidate is a new chemical entity (NCE). It is an orally active anti-fibrotic agent. The drug candidate targets transforming growth factor-beta (TGF-beta), platelet-derived growth factor (PDGF) and G protein coupled receptor 68 (GPR68). It was also under development for diabetic nephropathy, diabetic cardiomyopathy associated with cardiac fibrosis and hypertrophy. It was under development for the treatment of focal segmental glomerulosclerosis.
Certa Therapeutics overview
Certa Therapeutics is focused on the emerging field of medical science which uses genetic information to identify which patients will best respond to a specific treatment, commonly referred to as precision medicine. Certa is initially targeting kidney disease, where fibrosis (scarring) of the kidney leads to kidney failure and ultimately dialysis or kidney transplantation. Certa’s novel drugs block a receptor that is a key driver of this fibrosis. Certa is able to use genetic analysis to identify those patients that are most likely to benefit from the therapy, addressing a market worth around US$5 billion per annum.
For a complete picture of FT-011’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
